Biogen Pharmachem Industries L (BIOGEN.BO) Stock Analysis & Winston Score

Biogen Pharmachem Industries is an Indian company that operates primarily as a financial services and investment firm, with activities spanning lending, investment, and related financial products. It serves retail and institutional clients in India, offering financial intermediation and capital allocation services. Despite sharing a name with the well-known US biotechnology company Biogen, this is a separate and unrelated Indian entity listed on the Bombay Stock Exchange.

The company generates revenue through interest income, fees, and returns on its investment portfolio, which explains its unusually high gross margin. It operates mainly within India and is a relatively small firm with a market capitalization of around $0.3 billion. Its low return on invested capital of roughly 1% suggests the business is not yet deploying its capital very efficiently, and the key risk it faces is competition from larger, better-capitalized Indian financial institutions, as well as tightening regulatory oversight of non-banking financial companies in India.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-57.2% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-125.6% YoY

YoY Growth Rate

Earnings declining

Insider Activity

64.6%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$331M cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Biogen Pharmachem Industries L's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

438.3%

Premium pricing power — 438.3% gross margin

Operating Margin

-62.1%

Losing money on operations — -62.1%

ROCE

-0.4%

Weak — -0.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+24.7%

Fast-growing sales (24.7% YoY)

EPS YoY

+111.3%

Earnings growing fast (111.3% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

189%

Turns 189% of profit into real cash

FCF Margin

63.0%

Converts sales into free cash efficiently (63.0%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

23.7x

no trend

Growth-priced — P/E 23.7

P/E above the market average. People are paying up for expected growth.

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial